After an unsuccessful campaign against the statin Crestor the watchdogs at Public Citizen (along with some other experts) are now putting Pargluva fully in their crosshairs:
Public Citizen, along with the undersigned, urges the FDA not to approve muraglitazar before a careful examination of data from a 5-year randomized controlled trial. However, we question why a drug that an FDA medical officer has concluded causes dose-related edema, weight gain, and congestive heart failure needs to be approved for diabetic patients who are already at increased risk for cardiovascular adverse effects and who already have multiple drugs available to treat their conditions.
Read the full letter here:
http://www.citizen.org/publications/release.cfm?ID=7407&secID=1660&catID=126
Well, at least the spotlight has moved off poor Crestor. It's an ill wind!
No comments:
Post a Comment